Supra-physiological rhGH administration induces gender-related differences in the hypothalamus–pituitary–thyroid (HPT) axis in healthy individuals

P. Sgrò, M. Sansone, A. Parisi, A. Sartorio, A. Sansone, F. Romanelli, A. Lenzi, L. Di Luigi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: The use of recombinant human growth hormone (rhGH) is a common habit among athletes. While the effects of rhGH administration have been described with contrasting results in males, no data exist in females to date. The aim of the present study was to evaluate the effects of rhGH administration on TSH, FT4 and FT3 levels and the time requested to return to baseline values after treatment withdrawal. Methods: Twenty-one healthy trained male and female athletes were treated with 0.03 mg rhGH/kg body mass 6 days/week for 3 weeks. We collected blood samples immediately before the first daily rhGH administration, at 3, 4, 8, 15 and 21 days of treatment and at 3 and 9 days after rhGH withdrawal. Results: In males, rhGH administration induced a significant (p < 0.01) early and stable TSH decrease and IGF-I increase, and a delayed FT4 reduction without FT3 modification, suggesting a central regulatory mechanism. In females, rhGH administration induced a significant (p < 0.01) early and transient TSH decrease and IGF-I increase, and a transient reduction in FT4 without any changes in FT3 concentrations. rhGH withdrawal was associated with a prompt normalization of TSH and FT4 levels in males, while in females the effects of rhGH treatment had already disappeared during the last period of treatment. Conclusion: We suggest that rhGH inhibits TSH at central level both in males and females. The pattern of normalization was different in the two genders probably due to gonadal steroids modulation on GH-IGF-I axis.

Original languageEnglish
Pages (from-to)1383-1390
Number of pages8
JournalJournal of Endocrinological Investigation
Volume39
Issue number12
DOIs
Publication statusPublished - Dec 1 2016

Fingerprint

Human Growth Hormone
Growth Hormone
Insulin-Like Growth Factor I
Athletes
Therapeutics
Habits
Steroids

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Supra-physiological rhGH administration induces gender-related differences in the hypothalamus–pituitary–thyroid (HPT) axis in healthy individuals. / Sgrò, P.; Sansone, M.; Parisi, A.; Sartorio, A.; Sansone, A.; Romanelli, F.; Lenzi, A.; Di Luigi, L.

In: Journal of Endocrinological Investigation, Vol. 39, No. 12, 01.12.2016, p. 1383-1390.

Research output: Contribution to journalArticle

Sgrò, P. ; Sansone, M. ; Parisi, A. ; Sartorio, A. ; Sansone, A. ; Romanelli, F. ; Lenzi, A. ; Di Luigi, L. / Supra-physiological rhGH administration induces gender-related differences in the hypothalamus–pituitary–thyroid (HPT) axis in healthy individuals. In: Journal of Endocrinological Investigation. 2016 ; Vol. 39, No. 12. pp. 1383-1390.
@article{a72d778541054005a6ce7b07a619f48b,
title = "Supra-physiological rhGH administration induces gender-related differences in the hypothalamus–pituitary–thyroid (HPT) axis in healthy individuals",
abstract = "Purpose: The use of recombinant human growth hormone (rhGH) is a common habit among athletes. While the effects of rhGH administration have been described with contrasting results in males, no data exist in females to date. The aim of the present study was to evaluate the effects of rhGH administration on TSH, FT4 and FT3 levels and the time requested to return to baseline values after treatment withdrawal. Methods: Twenty-one healthy trained male and female athletes were treated with 0.03 mg rhGH/kg body mass 6 days/week for 3 weeks. We collected blood samples immediately before the first daily rhGH administration, at 3, 4, 8, 15 and 21 days of treatment and at 3 and 9 days after rhGH withdrawal. Results: In males, rhGH administration induced a significant (p < 0.01) early and stable TSH decrease and IGF-I increase, and a delayed FT4 reduction without FT3 modification, suggesting a central regulatory mechanism. In females, rhGH administration induced a significant (p < 0.01) early and transient TSH decrease and IGF-I increase, and a transient reduction in FT4 without any changes in FT3 concentrations. rhGH withdrawal was associated with a prompt normalization of TSH and FT4 levels in males, while in females the effects of rhGH treatment had already disappeared during the last period of treatment. Conclusion: We suggest that rhGH inhibits TSH at central level both in males and females. The pattern of normalization was different in the two genders probably due to gonadal steroids modulation on GH-IGF-I axis.",
author = "P. Sgr{\`o} and M. Sansone and A. Parisi and A. Sartorio and A. Sansone and F. Romanelli and A. Lenzi and {Di Luigi}, L.",
year = "2016",
month = "12",
day = "1",
doi = "10.1007/s40618-016-0489-6",
language = "English",
volume = "39",
pages = "1383--1390",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Springer International Publishing",
number = "12",

}

TY - JOUR

T1 - Supra-physiological rhGH administration induces gender-related differences in the hypothalamus–pituitary–thyroid (HPT) axis in healthy individuals

AU - Sgrò, P.

AU - Sansone, M.

AU - Parisi, A.

AU - Sartorio, A.

AU - Sansone, A.

AU - Romanelli, F.

AU - Lenzi, A.

AU - Di Luigi, L.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Purpose: The use of recombinant human growth hormone (rhGH) is a common habit among athletes. While the effects of rhGH administration have been described with contrasting results in males, no data exist in females to date. The aim of the present study was to evaluate the effects of rhGH administration on TSH, FT4 and FT3 levels and the time requested to return to baseline values after treatment withdrawal. Methods: Twenty-one healthy trained male and female athletes were treated with 0.03 mg rhGH/kg body mass 6 days/week for 3 weeks. We collected blood samples immediately before the first daily rhGH administration, at 3, 4, 8, 15 and 21 days of treatment and at 3 and 9 days after rhGH withdrawal. Results: In males, rhGH administration induced a significant (p < 0.01) early and stable TSH decrease and IGF-I increase, and a delayed FT4 reduction without FT3 modification, suggesting a central regulatory mechanism. In females, rhGH administration induced a significant (p < 0.01) early and transient TSH decrease and IGF-I increase, and a transient reduction in FT4 without any changes in FT3 concentrations. rhGH withdrawal was associated with a prompt normalization of TSH and FT4 levels in males, while in females the effects of rhGH treatment had already disappeared during the last period of treatment. Conclusion: We suggest that rhGH inhibits TSH at central level both in males and females. The pattern of normalization was different in the two genders probably due to gonadal steroids modulation on GH-IGF-I axis.

AB - Purpose: The use of recombinant human growth hormone (rhGH) is a common habit among athletes. While the effects of rhGH administration have been described with contrasting results in males, no data exist in females to date. The aim of the present study was to evaluate the effects of rhGH administration on TSH, FT4 and FT3 levels and the time requested to return to baseline values after treatment withdrawal. Methods: Twenty-one healthy trained male and female athletes were treated with 0.03 mg rhGH/kg body mass 6 days/week for 3 weeks. We collected blood samples immediately before the first daily rhGH administration, at 3, 4, 8, 15 and 21 days of treatment and at 3 and 9 days after rhGH withdrawal. Results: In males, rhGH administration induced a significant (p < 0.01) early and stable TSH decrease and IGF-I increase, and a delayed FT4 reduction without FT3 modification, suggesting a central regulatory mechanism. In females, rhGH administration induced a significant (p < 0.01) early and transient TSH decrease and IGF-I increase, and a transient reduction in FT4 without any changes in FT3 concentrations. rhGH withdrawal was associated with a prompt normalization of TSH and FT4 levels in males, while in females the effects of rhGH treatment had already disappeared during the last period of treatment. Conclusion: We suggest that rhGH inhibits TSH at central level both in males and females. The pattern of normalization was different in the two genders probably due to gonadal steroids modulation on GH-IGF-I axis.

UR - http://www.scopus.com/inward/record.url?scp=84994805920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994805920&partnerID=8YFLogxK

U2 - 10.1007/s40618-016-0489-6

DO - 10.1007/s40618-016-0489-6

M3 - Article

VL - 39

SP - 1383

EP - 1390

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

IS - 12

ER -